Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer
Lecia V. Sequist(Harvard University), Joan H. Schiller(Virginia Department of Health), Wallace Akerley(University of Utah), Joachim von Pawel(Asklepios Fachkliniken München-Gauting), С. В. Орлов(St Petersburg University), Susan Arthur(Beth Israel Deaconess Medical Center), Daniel B. Costa(Beth Israel Deaconess Medical Center), Brian Schwartz(Cyclacel Pharmaceuticals (United Kingdom)), Yinpu Chen(Arqule (United States)), David E. Gerber(Parkland Health & Hospital System), Igor Gorbachevsky(Beth Israel Deaconess Medical Center), Dora Ferrari(Beth Israel Deaconess Medical Center), Edward G. Garmey(ProteinQure (Canada)), Wolfram Brugger(University of Freiburg), Rodryg Ramlau(Poznan University of Medical Sciences)
Cited by 379
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k